BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boetto J, Peyre M, Kalamarides M. Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis. Acta Neurochir (Wien) 2021;163:57-66. [PMID: 33216210 DOI: 10.1007/s00701-020-04650-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Maier AD. Malignant meningioma. APMIS 2022;130:1-58. [DOI: 10.1111/apm.13276] [Reference Citation Analysis]
2 Gambacciani C, Grimod G, Sameshima T, Santonocito OS. Surgical management of skull base meningiomas and vestibular schwannomas. Curr Opin Oncol 2022. [PMID: 36093884 DOI: 10.1097/CCO.0000000000000904] [Reference Citation Analysis]
3 Teranishi Y, Okano A, Miyawaki S, Ohara K, Ishigami D, Hongo H, Dofuku S, Takami H, Mitsui J, Ikemura M, Komura D, Katoh H, Ushiku T, Ishikawa S, Shin M, Nakatomi H, Saito N. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. Acta Neuropathol Commun 2022;10:76. [PMID: 35570314 DOI: 10.1186/s40478-022-01377-w] [Reference Citation Analysis]
4 Lee KS, Zhang JJY, Kirollos R, Santarius T, Nga VDW, Yeo TT. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. Sci Rep 2022;12:1942. [PMID: 35121790 DOI: 10.1038/s41598-022-05773-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Passeri T, Giammattei L, Le Van T, Abbritti R, Perrier A, Wong J, Bourneix C, Polivka M, Adle-Biassette H, Bernat AL, Masliah-Planchon J, Mandonnet E, Froelich S. Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization. Acta Neurochir (Wien) 2022;164:255-63. [PMID: 34613529 DOI: 10.1007/s00701-021-05005-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 John P, Waldt N, Liebich J, Kesseler C, Schnabel S, Angenstein F, Sandalcioglu IE, Scherlach C, Sahm F, Kirches E, Mawrin C. AKT1E17K -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363. Neuropathol Appl Neurobiol 2021;:e12780. [PMID: 34837233 DOI: 10.1111/nan.12780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ho A, Tang H. Editorial: Meningioma: From Basic Research to Clinical Translational Study. Front Oncol 2021;11:750690. [PMID: 34745975 DOI: 10.3389/fonc.2021.750690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Boetto J, Birzu C, Kalamarides M, Peyre M, Sanson M. [Meningiomas: A review of current knowledge]. Rev Med Interne 2021:S0248-8663(21)00550-6. [PMID: 34272093 DOI: 10.1016/j.revmed.2021.06.011] [Reference Citation Analysis]